CR20120115A - Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog - Google Patents
Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehogInfo
- Publication number
- CR20120115A CR20120115A CR20120115A CR20120115A CR20120115A CR 20120115 A CR20120115 A CR 20120115A CR 20120115 A CR20120115 A CR 20120115A CR 20120115 A CR20120115 A CR 20120115A CR 20120115 A CR20120115 A CR 20120115A
- Authority
- CR
- Costa Rica
- Prior art keywords
- hedgehog
- combination therapy
- nanoparticules
- taxan
- inhibitors
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000027355 Ferocactus setispinus Species 0.000 title 1
- 241000289669 Erinaceus europaeus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000008410 smoothened signaling pathway Effects 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23681309P | 2009-08-25 | 2009-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120115A true CR20120115A (es) | 2012-09-04 |
Family
ID=43628371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120115A CR20120115A (es) | 2009-08-25 | 2012-03-12 | Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20130045240A1 (enExample) |
| EP (2) | EP2470173B1 (enExample) |
| JP (1) | JP2013503174A (enExample) |
| KR (1) | KR20120053052A (enExample) |
| CN (1) | CN102573832B (enExample) |
| AU (1) | AU2010286670B2 (enExample) |
| BR (1) | BR112012004149A2 (enExample) |
| CA (1) | CA2772301A1 (enExample) |
| CR (1) | CR20120115A (enExample) |
| DK (1) | DK2470173T3 (enExample) |
| ES (1) | ES2577024T3 (enExample) |
| HR (1) | HRP20160551T8 (enExample) |
| HU (1) | HUE029094T2 (enExample) |
| IL (1) | IL218316A (enExample) |
| IN (1) | IN2012DN02018A (enExample) |
| MX (1) | MX340670B (enExample) |
| MY (1) | MY162514A (enExample) |
| NI (1) | NI201200030A (enExample) |
| NZ (1) | NZ598588A (enExample) |
| PL (1) | PL2470173T3 (enExample) |
| PT (1) | PT2470173E (enExample) |
| RU (1) | RU2561055C2 (enExample) |
| SG (2) | SG10201609290PA (enExample) |
| UA (1) | UA110196C2 (enExample) |
| WO (1) | WO2011025838A1 (enExample) |
| ZA (1) | ZA201201531B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| US9675578B2 (en) | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP3417859A1 (en) * | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| CA3051495A1 (en) * | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| CN103221042B (zh) * | 2010-06-02 | 2016-02-10 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| CA2801891C (en) * | 2010-06-07 | 2020-10-27 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| WO2012151544A1 (en) | 2011-05-05 | 2012-11-08 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US9248128B2 (en) | 2012-01-27 | 2016-02-02 | New York University | Method for enhancing remyelination using GLI1 inhibitors |
| CN103570625A (zh) * | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| WO2014062511A1 (en) * | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014087413A1 (en) * | 2012-12-03 | 2014-06-12 | Vishwa Vidya Peetham University Amrita | Nanoparticles comprising sorafenib |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| JP6349381B2 (ja) * | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2014179678A1 (en) * | 2013-05-03 | 2014-11-06 | Angiostrass Llc | Methods of treating cancer and angioproliferative disorders |
| US10562912B2 (en) | 2013-06-05 | 2020-02-18 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| JP6434968B2 (ja) | 2013-07-02 | 2018-12-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| BR112016004450A2 (pt) * | 2013-09-17 | 2017-10-17 | Genentech Inc | métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor |
| GB201416513D0 (en) * | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| KR20160066490A (ko) | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| EA039121B1 (ru) | 2015-02-27 | 2021-12-07 | Куртана Фармасьютикалс, Инк. | ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2 |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| CN107709314A (zh) | 2015-06-11 | 2018-02-16 | 巴斯利尔药物国际股份公司 | 外排泵抑制剂及其治疗性用途 |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| CN106421786A (zh) * | 2015-08-06 | 2017-02-22 | 复旦大学 | Hedgehog通路抑制剂和纳米药物递送系统的药物组合物及其用途 |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| IL288591B2 (en) * | 2019-05-29 | 2026-05-01 | Nelum Corp | TAK-441 for use in cancer treatment in combination with other cancer therapies |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
| CN112755042A (zh) * | 2019-11-06 | 2021-05-07 | 绍兴维帆生物技术有限公司 | 一种抗肿瘤药物的联合使用治疗白血病的方法 |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| WO2025120550A1 (ko) * | 2023-12-08 | 2025-06-12 | 제이더블유중외제약 주식회사 | 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법 |
| CN122349526A (zh) * | 2023-12-08 | 2026-07-07 | Jw制药公司 | 用于制备杂环衍生物的中间化合物、其制备方法及使用其制备杂环衍生物的方法 |
| CN120177781B (zh) * | 2025-05-22 | 2025-08-12 | 南京师范大学 | 生物传感器及其应用和高通量筛选花姜酮生产菌的方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| WO1999000113A1 (en) * | 1997-06-27 | 1999-01-07 | Vivorx Pharmaceuticals, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US20070116761A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| DE69939327D1 (de) | 1998-11-02 | 2008-09-25 | Curis Inc | Funktionelle antagonisten von hedgehog-aktivität |
| US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| JP2002538167A (ja) | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | 脂質の代謝および貯蔵を調節する方法 |
| AU782493B2 (en) | 1999-06-01 | 2005-08-04 | Curis, Inc. | Polymer conjugates of hedgehog proteins and uses |
| US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| US20050192262A1 (en) * | 2001-03-13 | 2005-09-01 | Tomas Hagstrom | Treatment of tumours |
| EA007339B1 (ru) | 2001-07-27 | 2006-08-25 | Кьюэрис, Инк. | Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| AU2003231032B2 (en) | 2002-04-22 | 2008-07-10 | Johns Hopkins University School Of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| FR2850022B1 (fr) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| WO2006039569A1 (en) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
| CA2587489C (en) * | 2004-11-03 | 2013-12-31 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| CA2627129A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and bortezomib for treating cancer |
| AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| WO2008121102A2 (en) | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
| DE102006038747A1 (de) | 2006-08-17 | 2008-03-20 | Khs Ag | Dichtanordnung für eine Drehlagervorrichtung |
| JP4897518B2 (ja) | 2007-03-02 | 2012-03-14 | 株式会社ニチベイ | ブラインドの操作装置 |
| BRPI0808772A2 (pt) * | 2007-03-14 | 2014-08-12 | Exelixis Inc | Inibidores da via de hedgehog |
| US8536168B2 (en) * | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| ES2569941T3 (es) * | 2007-06-07 | 2016-05-13 | Novartis Ag | Derivados de bifenilcarboxamida como moduladores de la ruta de hedgehog |
| US20090123932A1 (en) * | 2007-11-09 | 2009-05-14 | Anne-Marie Mes-Masson | Quantitative test to detect disease progression markers of epithelial ovarian cancer patients |
| JP2011522773A (ja) | 2007-12-27 | 2011-08-04 | インフィニティ ファーマスーティカルズ、インク． | 治療剤での癌の処置方法 |
| EP2235063B1 (en) * | 2007-12-28 | 2015-09-02 | Genentech, Inc. | Anti-hedgehog antibodies |
-
2010
- 2010-08-25 BR BR112012004149A patent/BR112012004149A2/pt not_active Application Discontinuation
- 2010-08-25 PT PT108125931T patent/PT2470173E/pt unknown
- 2010-08-25 SG SG10201609290PA patent/SG10201609290PA/en unknown
- 2010-08-25 NZ NZ598588A patent/NZ598588A/en not_active IP Right Cessation
- 2010-08-25 RU RU2012111235/15A patent/RU2561055C2/ru active
- 2010-08-25 WO PCT/US2010/046684 patent/WO2011025838A1/en not_active Ceased
- 2010-08-25 US US13/392,501 patent/US20130045240A1/en not_active Abandoned
- 2010-08-25 EP EP10812593.1A patent/EP2470173B1/en active Active
- 2010-08-25 IN IN2018DEN2012 patent/IN2012DN02018A/en unknown
- 2010-08-25 CN CN201080045983.0A patent/CN102573832B/zh active Active
- 2010-08-25 MX MX2012002460A patent/MX340670B/es active IP Right Grant
- 2010-08-25 SG SG2012013157A patent/SG178873A1/en unknown
- 2010-08-25 CA CA2772301A patent/CA2772301A1/en not_active Abandoned
- 2010-08-25 MY MYPI2012000838A patent/MY162514A/en unknown
- 2010-08-25 HR HRP20160551TT patent/HRP20160551T8/hr unknown
- 2010-08-25 EP EP16167017.9A patent/EP3103452A1/en not_active Withdrawn
- 2010-08-25 UA UAA201203446A patent/UA110196C2/uk unknown
- 2010-08-25 KR KR1020127007526A patent/KR20120053052A/ko not_active Ceased
- 2010-08-25 HU HUE10812593A patent/HUE029094T2/hu unknown
- 2010-08-25 DK DK10812593.1T patent/DK2470173T3/en active
- 2010-08-25 JP JP2012526948A patent/JP2013503174A/ja active Pending
- 2010-08-25 PL PL10812593.1T patent/PL2470173T3/pl unknown
- 2010-08-25 ES ES10812593.1T patent/ES2577024T3/es active Active
- 2010-08-25 AU AU2010286670A patent/AU2010286670B2/en active Active
-
2012
- 2012-02-24 NI NI201200030A patent/NI201200030A/es unknown
- 2012-02-26 IL IL218316A patent/IL218316A/en active IP Right Grant
- 2012-02-29 ZA ZA2012/01531A patent/ZA201201531B/en unknown
- 2012-03-12 CR CR20120115A patent/CR20120115A/es unknown
-
2013
- 2013-02-28 US US13/781,487 patent/US20140072630A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG178873A1 (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| CO6321188A2 (es) | Tratamiento de cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de parp | |
| BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
| NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
| MY162903A (en) | Methods of treatment of pancreatic cancer | |
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| MX2017010773A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer. | |
| GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
| BR112012024349A2 (pt) | métodos de tratamento de carcinoma hepatocelular | |
| CR20120528A (es) | Métodos para tratar el cáncer | |
| GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| ECSP099376A (es) | Inhibidores de la actividad de la akt | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2013003076A (es) | Terapeuticos contra cancer de mama. | |
| MX359227B (es) | Tratamiento de cáncer con inhibidores de tor cinasa. | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| BR112012011823A2 (pt) | métodos e composições para tratar tumores sólidos e outras malignidades | |
| GT201200279A (es) | Combinaciones de principios activos | |
| ES2723778T3 (es) | Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos | |
| CR20140211A (es) | Terapia de combinación para cáncer de ovario | |
| DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek | |
| NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| GT201300148A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek |